The thyroid and liver are locked in a two-way metabolic partnership that most people never hear about until something goes wrong with one or both organs. Your liver is the main site where the thyroid’s primary hormone output gets converted into its active form, and thyroid hormones in turn regulate how the liver handles fat, cholesterol, and even drug breakdown. When either organ falters, the other often shows signs of trouble too. This relationship has become a particularly active area of research since the approval of a liver-targeted drug that mimics thyroid hormone action, bringing decades of basic science into the clinic.
Your Liver Is a Thyroid Hormone Processing Plant
The thyroid gland releases mostly thyroxine, commonly called T4, which is relatively inactive. For T4 to do its job throughout your body, it needs to be converted into triiodothyronine, or T3, the active form. The liver is one of the main places this conversion happens. It relies on enzymes called deiodinases, particularly type 1 deiodinase (Dio1), which is the most abundant deiodinase in the liver and is found primarily in hepatocytes, the liver’s workhorse cells.1Bioscientifica / European Thyroid Journal. Role of hepatic deiodinases in thyroid hormone homeostasis and liver metabolism, inflammation, and fibrosis Dio1 can both activate and inactivate thyroid hormones, giving the liver a kind of thermostat function over how much active T3 circulates.
The liver also handles the disposal side. Through a process called sulfate conjugation, the liver tags thyroid hormones for elimination. Sulfation accelerates the breakdown of iodothyronines by Dio1, making it a rate-limiting step in one of the body’s main pathways for clearing thyroid hormones.2Cell Press (Trends in Endocrinology & Metabolism). The thyroid and liver: a deep dive into their connection So the liver does not simply convert T4 to T3 and move on. It continuously adjusts the balance between producing active hormone and breaking it down. Anything that disrupts liver function can throw off that balance.
Hypothyroidism and Fatty Liver Disease
One of the most clinically significant consequences of this relationship is the link between an underactive thyroid and fat buildup in the liver, a condition now called metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD). The connection runs through several channels. When thyroid hormone levels drop, cholesterol metabolism slows. The liver’s LDL receptors become less active, so LDL cholesterol clearance declines and lipids accumulate in the bloodstream and in liver tissue.3PubMed Central. Profound Hypothyroidism as a Reversible Cause of Severe Low-Density Lipoprotein Cholesterol (LDL-C) Elevation Fat also builds up in liver cells because, without sufficient T3, the liver burns less fat for fuel.
At the molecular level, T3 drives fat oxidation in the liver through a receptor called thyroid hormone receptor-beta 1 (THRβ1). When T3 binds this receptor, it ramps up the production of enzymes that shuttle fatty acids into the mitochondria and peroxisomes to be burned.4Biochemical Pharmacology. The role of thyroid hormone receptor beta 1 (THRβ1) in metabolic dysfunction associated steatohepatitis (MASH): from dysregulation to therapeutic target – Section: 5. Molecular pathways regulated by THRβ1 in MASH With less T3 around, those fat-burning pathways slow down, and the liver starts stockpiling triglycerides instead of breaking them down.
The epidemiological data backs this up convincingly. A large meta-analysis found that primary hypothyroidism was associated with roughly a 40% higher odds of having MASLD, and the risk of progressing to the more serious inflammatory form of the disease or advanced fibrosis was nearly three times higher.5Gut. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis Even subclinical hypothyroidism, where TSH is elevated but T4 levels still look normal, carries increased risk. Research pooling data from over 44,000 people found that various definitions of hypothyroidism were all tied to a significant increase in MASLD, independent of the usual metabolic risk factors like obesity and diabetes.6PubMed Central. Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment The takeaway for anyone managing hypothyroidism: your liver health is worth monitoring, even if you feel fine otherwise.
When the Thyroid Runs Too Hot
Hyperthyroidism poses its own risks to the liver, though the picture is messier. Abnormal liver blood tests are surprisingly common in people with untreated thyrotoxicosis, with reported prevalence ranging from 15% to 76% depending on the study.7PubMed Central. Hyperthyroidism and Liver Dysfunction: A Review of a Common Comorbidity The wide range reflects the fact that multiple mechanisms can be at work simultaneously. Excess thyroid hormone can directly injure liver cells, likely by driving metabolic demand beyond what the liver’s blood supply can support. But the liver damage seen in hyperthyroid patients may also come from heart failure that develops as a complication, from autoimmune conditions that travel alongside Graves’ disease, or from the drugs used to treat the overactive thyroid.
That last point deserves its own mention. Propylthiouracil (PTU), one of the older anti-thyroid medications, carries a well-recognized risk of drug-induced liver injury. Modeling work has estimated that at a typical dose, roughly one in five patients may develop elevated liver enzymes, with oxidative stress proposed as an important toxic mechanism. Methimazole, the other main anti-thyroid drug, appears far less hepatotoxic by comparison.8Toxicology and Applied Pharmacology. Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach This distinction matters clinically: if you have pre-existing liver problems and need treatment for hyperthyroidism, the choice of medication is not trivial.
How Liver Disease Scrambles Thyroid Lab Results
The relationship also runs in the opposite direction. Chronic liver disease can produce a confusing set of thyroid lab results even when the thyroid gland itself is working fine. In people with cirrhosis, T3 and free T3 tend to be low, while thyroxine-binding globulin (the protein that carries thyroid hormones in the blood) and reverse T3 are elevated.9PubMed Central. Thyroid function tests in chronic liver disease: evidence for multiple abnormalities despite clinical euthyroidism Reverse T3 is an inactive form of thyroid hormone, and seeing it rise while T3 falls in cirrhosis reflects a shift in how the damaged liver processes T4: it shunts more T4 toward the inactive pathway instead of producing usable T3.
An older study measuring thyroid hormones across different stages of liver disease found this pattern most clearly in cirrhosis, where both T4 and T3 dropped and reverse T3 rose significantly. In fatty liver disease, T4 and T3 were also reduced, though without the telltale reverse T3 increase. Patients with chronic hepatitis, by contrast, showed elevated binding proteins and modestly increased total T4, reflecting changes in protein production rather than thyroid dysfunction per se.10SpringerLink / Journal of Endocrinological Investigation. Relations between serum levels of TSH, TBG, T4, T3, rT3 and various histologically classified chronic liver diseases
The clinical significance here is practical and easy to miss. A doctor seeing low T3 in a cirrhotic patient might be tempted to diagnose and treat hypothyroidism, but in most cases the thyroid is actually fine. Research has confirmed that euthyroidism, meaning normal thyroid function, is almost always maintained in chronic liver disease despite the abnormal-looking numbers.9PubMed Central. Thyroid function tests in chronic liver disease: evidence for multiple abnormalities despite clinical euthyroidism Treating someone with thyroid hormone replacement when they do not actually need it can cause harm, so understanding this diagnostic trap matters.
Autoimmune Diseases That Hit Both Organs
Autoimmune conditions have a tendency to cluster, and the thyroid and liver are no exception. Primary biliary cholangitis (PBC), an autoimmune disease that gradually destroys the small bile ducts in the liver, frequently co-occurs with thyroid disorders. Between roughly 6% and 24% of PBC patients have a thyroid condition, with hypothyroidism being the most common. In one study, over 20% of PBC patients had Hashimoto’s thyroiditis, the autoimmune form of hypothyroidism.11Gut and Liver. Extrahepatic Manifestations of Primary Biliary Cholangitis
The overlap goes beyond statistical coincidence. Both Hashimoto’s thyroiditis and PBC involve the immune system generating antibodies against the body’s own tissues, and they share genetic susceptibility regions. If you have been diagnosed with PBC, screening for thyroid dysfunction is standard practice, and the reverse is worth considering too. Autoimmune hepatitis, a different liver condition, also shows higher-than-expected rates of concurrent thyroid autoimmunity, though the numbers are less well established than for PBC.
Thyroid Hormones and Liver Scarring
Beyond fat accumulation, thyroid hormones play a direct role in liver fibrosis, the scarring process that can eventually lead to cirrhosis. Fibrosis is driven largely by hepatic stellate cells, which become activated in response to injury and start depositing collagen and other structural proteins. Thyroid hormones appear to put the brakes on this process. In laboratory experiments, T3 blunted the fibrogenic response of stellate cells to TGF-beta, one of the most potent pro-scarring signals in the body, and this protective effect depended on the thyroid hormone receptor alpha (TRα) being present.12PubMed. Thyroid hormone receptor alpha modulates fibrogenesis in hepatic stellate cells
More broadly, thyroid hormones regulate stellate cell activation, inflammation, and the remodeling of the liver’s structural scaffold through both direct gene-level effects and faster non-genomic signaling pathways.13PubMed Central. Navigating thyroid hormone signaling in liver fibrosis: mechanisms and clinical implications The implication is that a hypothyroid state, by reducing the supply of T3 to the liver, may remove a natural check on fibrosis progression. This adds another layer to why hypothyroidism is associated not just with fatty liver but with the more dangerous downstream consequences of ongoing liver injury.
Gallstones and an Underactive Thyroid
A less well-known extension of the thyroid-liver connection involves the gallbladder. Hypothyroidism has been linked to a higher risk of gallstone formation, and the mechanism is surprisingly direct. The sphincter of Oddi, the muscular valve that controls bile flow from the liver and gallbladder into the small intestine, appears to be sensitive to thyroid status. In a hypothyroid state, the sphincter is less inclined to relax, causing bile to stagnate. Over time, this stasis allows bile to become supersaturated with cholesterol, eventually crystallizing into stones.14PubMed Central. A Review of Synchronous Findings of Hypothyroidism and Cholelithiasis Hypothyroidism also reduces overall bile secretion and alters cholesterol metabolism in ways that compound the problem. For someone with unexplained gallstones, especially at a younger age, checking thyroid function is a reasonable step.
Resmetirom and the New Era of Thyroid-Targeted Liver Therapy
Perhaps the most striking proof of how tightly the thyroid and liver are linked is the development of resmetirom, the first drug approved specifically for the inflammatory form of fatty liver disease (MASH) with moderate-to-advanced fibrosis.15PubMed. Pharmacokinetics, mass balance and metabolic profiling of resmetirom in healthy subjects and nonclinical metabolism and disposition Resmetirom is a selective agonist of the THRβ receptor, the same receptor through which T3 drives fat burning in liver cells. The idea is elegant: mimic what thyroid hormone does in the liver, specifically, without cranking up thyroid activity in the heart, bones, or brain.
The pivotal trial demonstrated that MASH resolution without worsening fibrosis was achieved in about 26% of patients taking 80 mg of resmetirom and 30% of patients taking 100 mg, compared with about 10% on placebo. Fibrosis markers also improved, with significant reductions in liver stiffness and collagen-related biomarkers.16Scientific Reports. Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis The drug essentially simulates localized hyperthyroidism in the liver, pushing fat oxidation up and lipid accumulation down, without the racing heartbeat and bone loss that systemic thyroid hormone excess would cause.17PubMed Central. Resmetirom: The First Disease-Specific Treatment for MASH
Resmetirom’s approval in 2024 marked a shift in how liver disease is treated, but it also validated a concept researchers had been exploring for years: that the liver’s dependence on thyroid hormone signaling is so fundamental that restoring or enhancing that signaling can reverse disease even when the thyroid gland itself is healthy. Interestingly, lab research has shown that some of thyroid hormones’ lipid-lowering effects in liver cells may not even require the classical receptors at all, occurring through non-receptor pathways.18PubMed. Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells This suggests that the full story of how thyroid signaling governs liver fat metabolism is still being worked out, and future drugs might target different parts of this machinery.
How Thyroid Status Affects Drug Metabolism
Beyond fat and cholesterol, thyroid status quietly shapes how the liver processes medications. The liver’s cytochrome P450 enzymes, responsible for breaking down a huge range of drugs, are sensitive to thyroid hormone levels. In hypothyroid animal models, some of these enzymes are suppressed while others are upregulated, creating an unpredictable shift in how quickly drugs are metabolized.19PubMed Central. Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice The opposing responses of the receptors that regulate these enzymes may partially cancel each other out, preventing catastrophic metabolic disruption, but the net effect can still change how long a drug stays active in the body or how much of it reaches its target.
For patients on medications with narrow therapeutic windows, things like blood thinners, seizure drugs, or certain heart medications, a significant swing in thyroid function could alter drug levels enough to matter. This is one of those practical considerations that rarely makes it into patient education materials but shows up in adverse events when thyroid status changes and drug doses are not re-evaluated.
Timing Matters at the Cellular Level
Emerging research is beginning to reveal that the liver’s response to thyroid hormone is not constant throughout the day. In liver cell experiments, T3 had different effects on the expression of metabolic genes depending on when the hormone was applied, suggesting that the liver’s internal clock gates how it responds to thyroid signaling.20PubMed Central. Circadian Gating of Thyroid Hormone Action in Hepatocytes Under conditions mimicking a fatty liver, this time-dependent pattern shifted further, and the circadian rhythm of the cells themselves lengthened. The clinical relevance is still speculative, but it raises the question of whether the timing of thyroid hormone replacement or liver-directed therapies could eventually matter as much as the dose.
The Neonatal Window and Lifelong Liver Programming
Perhaps the most surprising chapter in the thyroid-liver story involves the very beginning of life. Research in mice has shown that thyroid hormone activity during the first few days after birth directly shapes the liver’s gene expression for the rest of the animal’s life. When the enzyme responsible for local T3 production in the liver was knocked out specifically during the neonatal period, the result was widespread changes in DNA methylation and chromatin accessibility in the adult liver, affecting over 1,300 genes.21Nature Communications. Neonatal thyroxine activation modifies epigenetic programming of the liver In other words, thyroid hormone during those first days was acting as an epigenetic programmer, flipping molecular switches that stayed flipped long after the initial hormone surge passed. This finding carries implications for neonatal hypothyroidism screening and treatment, suggesting that the liver may be one of the organs most sensitive to thyroid hormone timing during early development.